03.25.15
A consortium led by the Centre for Process Innovation (CPI) on behalf of UCB Celltech, Lonza Biologics, and partner Horizon Discovery Group, have been awarded £6.2 million as part of the Advanced Manufacturing Supply Chain Initiative (AMSCI).
The AMSCI program provides grant funding from the UK Government to support the future needs of biologics manufacturing in the UK. This initiative supports the development of next-generation production systems so that the most efficacious and cost-effective therapies are made available to patients.
Horizon will receive as much as £652,000 to expand bioproductionresearch. Horizon will use its gene editing and screening expertise to develop a high throughput platform to accelerate the development of novel and improved Chinese Hamster Ovary (CHO) cell lines, with the goal of allowing better decisions to be made on potential performance improvements for biologic drug manufacturing.
Dr. Paul Morrill, president, Products, Horizon Discovery Group, said, “Horizon, along with UCB and the other consortium partners, recognizes the importance of strengthening the biomanufacturing supply chain in order to deliver the next generation of biological medicines. Enhancing cell line function through gene editing is a critical path activity towards this outcome. This initiative, alongside the recent Industrial Biotechnology Catalyst funding, further reinforces Horizon’s reputation as a driver of innovation for biomanufacturing.”
The AMSCI program provides grant funding from the UK Government to support the future needs of biologics manufacturing in the UK. This initiative supports the development of next-generation production systems so that the most efficacious and cost-effective therapies are made available to patients.
Horizon will receive as much as £652,000 to expand bioproductionresearch. Horizon will use its gene editing and screening expertise to develop a high throughput platform to accelerate the development of novel and improved Chinese Hamster Ovary (CHO) cell lines, with the goal of allowing better decisions to be made on potential performance improvements for biologic drug manufacturing.
Dr. Paul Morrill, president, Products, Horizon Discovery Group, said, “Horizon, along with UCB and the other consortium partners, recognizes the importance of strengthening the biomanufacturing supply chain in order to deliver the next generation of biological medicines. Enhancing cell line function through gene editing is a critical path activity towards this outcome. This initiative, alongside the recent Industrial Biotechnology Catalyst funding, further reinforces Horizon’s reputation as a driver of innovation for biomanufacturing.”